Cargando…
Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
BACKGROUND: Combination therapy with immune checkpoint inhibitors (ICIs) may benefit approximately 10-20% of microsatellite-stable colorectal cancer (MSS-CRC) patients. However, there is a lack of optimal biomarkers. This study aims to understand the predictive value of epigenetic-related gene mutat...
Autores principales: | Liu, Chao, Xiao, Huiting, Cui, Luying, Fang, Lin, Han, Shuling, Ruan, Yuli, Zhao, Wenyuan, Zhang, Yanqiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720302/ https://www.ncbi.nlm.nih.gov/pubmed/36479108 http://dx.doi.org/10.3389/fimmu.2022.1039631 |
Ejemplares similares
-
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021) -
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
por: Ghiringhelli, François, et al.
Publicado: (2019) -
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
por: Hermel, David J., et al.
Publicado: (2019) -
The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021) -
Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)